DUBLIN, Calif., Jan. 2 Microchip Biotechnologies, Inc.(MBI) has been selected for participation in the inaugural US ArmyCommercialization Pilot Program. The Commercialization Pilot Program is a newprogram to identify SBIR firms that have Phase II projects with hightransition potential to commercial products that meet high priority Armyrequirements. MBI was identified as one of 25 firms selected out of 529eligible firms and 416 applicants (http://www.armysbir.com/sbir/cpp_fy08.htm).MBI has been developing a biothreat detection system under Army SBIR funding."The acceptance of MBI by the Army to participate in the CPP is a furthervalidation of our commitment to develop and commercialize microfluidictechnologies for the protection of the combat troops and civilianpopulations," said Dr. Stevan Jovanovich, President and CEO of MBI.
About Microchip Biotechnologies, Inc.
Microchip Biotechnologies, Inc. is a privately-held company located inDublin, California that is developing the Apollo next-generation fluidicsplatform for Life Sciences, Applied Sciences, and Diagnostics markets. TheApollo platform integrates advanced microfluidic sample preparation andanalytical capabilities to produce sample-to-answer performance for DNAsequencing, biodefense, forensics, and molecular diagnostics applications.The Apollo platform incorporates MBI's proprietary BeadStorm(TM) bead-basedsample preparation devices and "Microscale On-Chip" (MOV(TM)) valves, pumps,and routers on microchips. More details can be found on the Company'swebsite: http://www.microchipbiotech.com.
SOURCE Microchip Biotechnologies, Inc.